This document provides updated tables for the CLSI antimicrobial susceptibility testing standard VET01.

An informational supplement for global application developed through the Clinical and Laboratory Standards Institute consensus process.
The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing clinical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement, but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advancements in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential, and may be submitted by anyone, at any time, on any document. All comments are addressed according to the consensus process by a committee of experts.

Appeals Process

If it is believed that an objection has not been adequately addressed, the process for appeals is documented in the CLSI Standards Development Policies and Processes.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute
950 West Valley Road, Suite 2500
Wayne, PA 19087 USA
P: 610.688.0100
F: 610.688.0700
www.clsi.org
standard@clsi.org
Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals

Abstract

The supplemental information presented in this document is intended for use with the antimicrobial disk and dilution testing procedures published in CLSI document VET01—Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals; Approved Standard—Fourth Edition.

The tabular information in this document presents the most current information for drug selection, interpretation, and QC. Additional supplements will publish as more veterinary-specific information becomes available. As such, users should ensure that the most current versions of the tables replace previously published tables. For ease of use, changes in the tables since the previous edition appear in boldface type.


The data in the supplement’s interpretive tables are valid only if the methodology is followed in CLSI document VET01—Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals; Approved Standard—Fourth Edition.
Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals

Mark G. Papich, DVM, MS
Shabbir Simjee, PhD
Mike Apley, DVM, PhD
Timothy S. Frana, DVM, MS, MPH, PhD
Cynthia C. Knapp, MS
Brian V. Lubbers, DVM, PhD, DACVCP
Markus Rose, DVM, PhD
Stefan Schwarz, DVM
Peter Silley, PhD
Michael T. Sweeney, MS
Maria M. Traczewski, BS, MT(ASCP)
John D. Turnidge, MD
Jeffrey L. Watts, PhD, RM(NRCM)
Contents

Committee Membership ................................................................. 5

Summary of Changes .......................................................................... 11

Abbreviations and Acronyms ........................................................... 14

Table 1. Antimicrobial Agents That Could Be Considered for Routine Testing by Veterinary Microbiology Laboratories ................................................................. 16

Table 2A. Zone Diameter and Minimal Inhibitory Concentration Interpretive Standards for *Enterobacteriaceae* ................................................................. 22

Table 2B. Zone Diameter and Minimal Inhibitory Concentration Interpretive Standards for *Pseudomonas aeruginosa* ............................................................. 30

Table 2C. Zone Diameter and Minimal Inhibitory Concentration Interpretive Standards for *Staphylococcus* spp. ................................................................. 34

Table 2D. Zone Diameter and Minimal Inhibitory Concentration Interpretive Standards for *Streptococcus* spp. ................................................................. 44

Table 2E. Zone Diameter and Minimal Inhibitory Concentration Interpretive Standards for *Enterococcus* spp. ................................................................. 54

Table 2F. Zone Diameter and Minimal Inhibitory Concentration Interpretive Standards for *Bordetella bronchiseptica* ................................................................. 58

Table 2G. Zone Diameter and Minimal Inhibitory Concentration Interpretive Standards for *Mannheimia haemolytica* ................................................................. 60

Table 2H. Zone Diameter and Minimal Inhibitory Concentration Interpretive Standards for *Pasteurella multocida* ................................................................. 62

Table 2I. Zone Diameter and Minimal Inhibitory Concentration Interpretive Standards for *Actinobacillus pleuropneumoniae* ................................................................. 66

Table 2J. Zone Diameter and Minimal Inhibitory Concentration Interpretive Standards for *Histophilus somni* ................................................................. 68

Table 3. Culture Collection Numbers for Organisms Used for Quality Control of Antimicrobial Susceptibility Tests ................................................................. 70

Table 4. Acceptable Quality Control Ranges of Antimicrobial Disk Susceptibility Test Zone Diameters (mm) for Reference Strains on Mueller-Hinton Agar (Except Where Noted) ................................................................. 72

Table 4A. Acceptable Quality Control Ranges of Antimicrobial Disk Susceptibility Test Zone Diameters (mm) for Testing *Campylobacter jejuni* ATCC® 33560 at 36 to 37°C for 24 Hours ................................................................. 74

Table 5. Acceptable Quality Control Ranges of Minimal Inhibitory Concentrations for Broth Microdilution (µg/mL) for Reference Strains ................................................................. 76
Contents (Continued)

Table 5A. Acceptable Quality Control Ranges of Minimal Inhibitory Concentrations (µg/mL) for the Agar Dilution Method of Testing *Campylobacter jejuni* ATCC® 33560 ........................................... 78

Table 5B. Acceptable Quality Control Ranges of Minimal Inhibitory Concentrations (µg/mL) for the Broth Microdilution Susceptibility Method of Testing *Campylobacter jejuni* ATCC® 33560 ........ 80

Table 5C. Acceptable Quality Control Ranges of Minimal Inhibitory Concentrations (µg/mL) for Anaerobic Reference Strains Using Agar Dilution .................................................. 82

Table 5D. Acceptable Quality Control Ranges of Minimal Inhibitory Concentrations (µg/mL) for Anaerobic Reference Strains Using Broth Microdilution .................................................. 82

Table 6. Acceptable Quality Control Ranges for *Histophilus somni* and *Actinobacillus pleuropneumoniae* .................................................................................................................. 84

Table 7. Standard Methods for Susceptibility Testing of Some Fastidious and Special Problem Veterinary Pathogens ........................................................................................................... 86

Table 8. Solvents and Diluents for Preparation of Stock Solutions of Antimicrobial Agents Requiring Solvents Other Than Water ............................................................................. 88

Table 9A. Screening and Confirmatory Tests for Extended-Spectrum β-Lactamase–Producing *Klebsiella pneumoniae*, *K. oxytoxa*, *Escherichia coli*, and *Proteus mirabilis* (Zone Diameter) .................. 90

Table 9B. Screening and Confirmatory Tests for Extended-Spectrum β-Lactamase–Producing *Klebsiella pneumoniae*, *K. oxytoxa*, *Escherichia coli*, and *Proteus mirabilis* (Minimal Inhibitory Concentration) ................................................................. 92

Table 9C. Screening Tests for Oxacillin Resistance and Reduced Susceptibility to Vancomycin in *Staphylococcus aureus* ........................................................................................................... 94

Table 9D. Disk Diffusion Test for Prediction of mecA-Mediated Resistance in Staphylococci ........ 96

Table 9E. Screening Tests for β-Lactamase Production in *Staphylococcus aureus* .......................... 98

Table 9F. Screening Tests for β-Lactamase Production in Coagulase-Negative *Staphylococcus* spp ................................................................................................................................. 102

Table 9G. Screening Tests for Inducible Resistance to Clindamycin ........................................... 104

Table 9H. Disk Diffusion Screening Tests for High-Level Aminoglycoside Resistance in *Enterococcus* spp ....................................................................................................................... 106

Table 9I. Minimal Inhibitory Concentration Screening Tests for High-Level Aminoglycoside Resistance and Vancomycin Resistance in *Enterococcus* spp ..................................................... 108

Glossary 1. Antimicrobial Class, Antimicrobial Subclass Designation, Antimicrobial Agents, and Antimicrobial Resistance Mechanisms ........................................................................................................... 110

Glossary 2. Abbreviations Commonly Used for Antimicrobial Agents Incorporated Into Disks or Susceptibility Panels ........................................................................................................ 113
Contents (Continued)

The Quality Management System Approach ........................................................................................................ 116

Related CLSI Reference Materials ....................................................................................................................... 117
Summary of Changes

This list includes the “major” changes in this document. Other minor or editorial changes were made to the general formatting and to some of the table footnotes and comments. Changes to the tables since the previous edition appear in boldface type.

Additions, Changes, and Deletions
The following are additions or changes unless otherwise noted as a “deletion.”

Table 1 – Antimicrobial Agents That Could Be Considered for Routine Testing by Veterinary Microbiology Laboratories

Group A:
Swine:
Added tildipirosin and penicillin G.

Cattle:
Added gamithromycin and tildipirosin.

Horses:
Added amikacin.

Dogs and Cats:
Added amikacin (dogs only), pradofloxacin, doxycycline (dogs only), and tetracycline (dogs only).

Changed amoxicillin-clavulanate from dogs and cats to dogs only.

Group B:
Dogs and Cats:
Changed amikacin from dogs and cats to cats only.

Added doxycycline (cats only).

Changed tetracycline from dogs and cats to cats only.

Group D:
Dogs and Cats:
Added cephalexin.

Tables 2A Through 2J (Interpretive Criteria)

For this edition of VET01S, the interpretive criteria tables are separated by organism, with each table further subdivided by drug class and animal species.

Enterobacteriaceae (Table 2A):
Updated recommendations for placement of disks on a 100-mm plate.
Summary of Changes (Continued)

Added information on the use of interpretive criteria based on human data (gray-shaded) only when the animal species/antimicrobial agent combinations are not listed in the table.

Added new amikacin minimal inhibitory concentration (MIC) interpretive criteria with dosing regimen for dogs and horses (foals and adults).

Added information on the appropriate use of amoxicillin or amoxicillin-clavulanate in dogs for treating infections caused by *Escherichia coli*.

Added new pradofloxacin disk diffusion and MIC interpretive criteria for dogs and cats.

*Pseudomonas aeruginosa* (Table 2B):
Added information on the use of interpretive criteria based on human data (gray-shaded) only when the animal species/antimicrobial agent combinations are not listed in the table.

Added new amikacin MIC interpretive criteria with dosing regimen for dogs and horses (foals and adults).

*Staphylococcus* spp. (Table 2C):
Added information on the use of interpretive criteria based on human data (gray-shaded) only when the animal species/antimicrobial agent combinations are not listed in the table.

Added new amikacin MIC interpretive criteria with dosing regimen for dogs and horses (foals and adults).

Added new pradofloxacin disk diffusion and MIC interpretive criteria for dogs and cats.

Added new doxycycline disk diffusion and MIC interpretive criteria with dosing regimen for dogs.

Added new tetracycline disk diffusion and MIC interpretive criteria for dogs with testing and reporting information.

*Streptococcus* spp. (Table 2D):
Added information on the use of interpretive criteria based on human data (gray-shaded) only when the animal species/antimicrobial agent combinations are not listed in the table.

Added new amikacin MIC interpretive criteria with dosing regimen for dogs and horses (foals and adults).

Added new penicillin G MIC interpretive criteria with dosing regimen for swine.

Added new pradofloxacin disk diffusion and MIC interpretive criteria for cats.

*Enterococcus* spp. (Table 2E):
Added information on disk placement and zone reading.

Added warning for testing and reporting information for cephalosporins, aminoglycosides, clindamycin, and trimethoprim-sulfamethoxazole.

Provided information for predicting synergy between ampicillin, penicillin, or vancomycin and an aminoglycoside.

*Bordetella bronchiseptica* (Table 2F):
Noted antimicrobial agents with *B. bronchiseptica*–specific interpretive criteria.
Summary of Changes (Continued)

Added new tildipirosin disk diffusion and MIC interpretive criteria for swine.

*Mannheimia haemolytica* (Table 2G):
Added new gamithromycin disk diffusion and MIC interpretive criteria for cattle.

Added new tildipirosin disk diffusion and MIC interpretive criteria for cattle.

*Pasteurella multocida* (Table 2H):
Added new penicillin G MIC interpretive criteria with dosing regimen for swine.

Added new pradofloxacin disk diffusion and MIC interpretive criteria for cats.

Added new gamithromycin disk diffusion and MIC interpretive criteria for cattle.

Added new tildipirosin disk diffusion and MIC interpretive criteria for cattle and swine.

*Actinobacillus pleuropneumoniae* (Table 2I):
Added information on placement of disks and reading of zones.

Added new tildipirosin MIC interpretive criteria for swine.

*Histophilus somni* (Table 2J):
Added new gamithromycin disk diffusion and MIC interpretive criteria for cattle.

Added new tildipirosin disk diffusion and MIC interpretive criteria for cattle.

**Tables 4 and 5 – Quality Control**

QC ranges added for:

**Table 4:**  
Added QC ranges for:

*E. coli* ATCC® 25922  
Cefoperazone

*Staphylococcus aureus* ATCC® 25923  
Cefoperazone

*S. aureus* ATCC® 25923  
Tylosin

**Table 5:**  
Added QC ranges for:

*Enterococcus faecalis* ATCC® 29212  
Avilamycin

*S. aureus* ATCC® 29213  
Cephalexin
Summary of Changes (Continued)

E. coli ATCC® 25922
Cephalexin

Table 5D:
Added QC range for:

C. difficile ATCC® 700057
Avilamycin

Table 8 – Solvents and Diluents

Added pradofloxacin.

Glossary 1

Added cefoperazone.

Abbreviations and Acronyms

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>ATCC®a</td>
<td>American Type Culture Collection</td>
</tr>
<tr>
<td>BHI</td>
<td>Brain Heart Infusion</td>
</tr>
<tr>
<td>CAMHB</td>
<td>cation-adjusted Mueller-Hinton broth</td>
</tr>
<tr>
<td>CoNS</td>
<td>coagulase-negative staphylococci</td>
</tr>
<tr>
<td>DNA</td>
<td>deoxyribonucleic acid</td>
</tr>
<tr>
<td>ESBL</td>
<td>extended-spectrum β-lactamase</td>
</tr>
<tr>
<td>HLAR</td>
<td>high-level aminoglycoside resistance</td>
</tr>
<tr>
<td>I</td>
<td>intermediate</td>
</tr>
<tr>
<td>IM</td>
<td>intramuscularly</td>
</tr>
<tr>
<td>IV</td>
<td>intravenously</td>
</tr>
<tr>
<td>LHB</td>
<td>lysed horse blood</td>
</tr>
<tr>
<td>MHA</td>
<td>Mueller-Hinton agar</td>
</tr>
<tr>
<td>MIC</td>
<td>minimal inhibitory concentration</td>
</tr>
<tr>
<td>MRSA</td>
<td>methicillin-resistant Staphylococcus aureus</td>
</tr>
<tr>
<td>PBP 2a</td>
<td>penicillin-binding protein 2a</td>
</tr>
<tr>
<td>PCR</td>
<td>polymerase chain reaction</td>
</tr>
<tr>
<td>PD</td>
<td>pharmacodynamic</td>
</tr>
<tr>
<td>PK</td>
<td>pharmacokinetic</td>
</tr>
<tr>
<td>PK-PD</td>
<td>pharmacokinetic-pharmacodynamic</td>
</tr>
<tr>
<td>QA</td>
<td>quality assurance</td>
</tr>
<tr>
<td>QC</td>
<td>quality control</td>
</tr>
<tr>
<td>R</td>
<td>resistant</td>
</tr>
<tr>
<td>RNA</td>
<td>ribonucleic acid</td>
</tr>
<tr>
<td>S</td>
<td>susceptible</td>
</tr>
<tr>
<td>SC</td>
<td>subcutaneously</td>
</tr>
<tr>
<td>UTI</td>
<td>urinary tract infection</td>
</tr>
<tr>
<td>VFM</td>
<td>veterinary fastidious medium</td>
</tr>
</tbody>
</table>

a ATCC® is a registered trademark of the American Type Culture Collection.
The Quality Management System Approach

Clinical and Laboratory Standards Institute (CLSI) subscribes to a quality management system (QMS) approach in the development of standards and guidelines, which facilitates project management; defines a document structure via a template; and provides a process to identify needed documents. The QMS approach applies a core set of “quality system essentials” (QSEs), basic to any organization, to all operations in any health care service’s path of workflow (ie, operational aspects that define how a particular product or service is provided). The QSEs provide the framework for delivery of any type of product or service, serving as a manager’s guide. The QSEs are as follows:

- **Organization**
- **Customer Focus**
- **Facilities and Safety**
- **Personnel**
- **Purchasing and Inventory**
- **Equipment**
- **Process Management**
- **Documents and Records**
- **Information Management**
- **Nonconforming Event Management**
- **Assessments**
- **Continual Improvement**

VET01S does not address any of the QSEs. For a description of the documents listed in the grid, please refer to the Related CLSI Reference Materials section on the following page.

### Path of Workflow

A path of workflow is the description of the necessary processes to deliver the particular product or service that the organization or entity provides. A laboratory path of workflow consists of the sequential processes: preexamination, examination, and postexamination and their respective sequential subprocesses. All laboratories follow these processes to deliver the laboratory’s services, namely quality laboratory information.

VET01S addresses the clinical laboratory path of workflow steps indicated by an “X.” For a description of the other documents listed in the grid, please refer to the Related CLSI Reference Materials section on the following page.
Related CLSI Reference Materials*

M11  Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria. 8th ed., 2012. This standard provides reference methods for the determination of minimal inhibitory concentrations of anaerobic bacteria by agar dilution and broth microdilution.


VET01  Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals. 4th ed., 2013. This document provides the currently recommended techniques for antimicrobial agent disk and dilution susceptibility testing, criteria for quality control testing, and interpretive criteria for veterinary use.

* CLSI documents are continually reviewed and revised through the CLSI consensus process; therefore, readers should refer to the most current editions.
Explore the Latest Offerings From CLSI!

As we continue to set the global standard for quality in laboratory testing, we are adding products and programs to bring even more value to our members and customers.

By becoming a CLSI member, your laboratory will join 1,600+ other influential organizations all working together to further CLSI’s efforts to improve health care outcomes. You can play an active role in raising global laboratory testing standards—in your laboratory, and around the world.

Find out which membership option is best for you at www.clsi.org/membership.

Find what your laboratory needs to succeed! CLSI U provides convenient, cost-effective continuing education and training resources to help you advance your professional development. We have a variety of easy-to-use, online educational resources that make eLearning stress-free and convenient for you and your staff.

See our current educational offerings at www.clsi.org/education.

When laboratory testing quality is critical, standards are needed and there is no time to waste. eCLIPSE™ Ultimate Access, our cloud-based online portal of the complete library of CLSI standards, makes it easy to quickly find the CLSI resources you need.

Learn more and purchase eCLIPSE at shop.clsi.org/eCLIPSE-Ultimate-Access.

For more information, visit www.clsi.org today.